biotech / news / / India Today
CRISPR is a revolutionary gene-editing technology that allows scientists to locate and correct errors in DNA.
BIRSA 101 uses a custom enzyme, enFnCas9, designed at CSIR-IGIB for greater gene-editing precision.
KEY POINTS
- Genome-wide studies show BIRSA 101 achieves up to 1,000-fold fewer off-target edits than existing CRISPR tools.
- Unlike Casgevy, BIRSA 101 directly repairs the sickle cell mutation, not just boosting fetal hemoglobin.
- BIRSA 101 could cost around Rs 50 lakh per patient, about 15-20 times cheaper than Casgevy.
- Phase 1 human trials of BIRSA 101 are imminent, aiming for a potentially one-time, lifelong cure.
COMPANIES
Summarized by Newsio from India Today. How we summarize →